CYLD regulates noscapine activity in acute lymphoblastic leukemia via a microtubule-dependent mechanism

Theranostics

Volumn 5, Issue 7, 2015, Pages 656-666

  Yang, Yunfan ^a   Ran, Jie ^a   Sun, Lei ^a   Sun, Xiaodong ^b   Luo, Youguang ^a   Yan, Bing ^a   Tala, ^a   Liu, Min ^a   Li, Dengwen ^a   Zhang, Lei ^c   Bao, Gang ^b   Zhou, Jun ^a,b  

^a NANKAI UNIVERSITY   (China)

^b Emory University   (United States)

^c INSTITUTE OF HEMATOLOGY AND BLOOD DISEASES HOSPITAL   (China)

Author keywords

Apoptosis; Leukemia; Microtubule; Mitotic arrest; Noscapine

Indexed keywords

MICROTUBULE ASSOCIATED PROTEIN; NOSCAPINE; PACLITAXEL; SMALL INTERFERING RNA; VINBLASTINE; CYLD PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; APOPTOSIS; ARTICLE; BINDING AFFINITY; CANCER COMBINATION CHEMOTHERAPY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYLD GENE; DRUG BINDING; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; GENE EXPRESSION; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; LEUKEMIA CELL; MICROTUBULE ASSEMBLY; MITOSIS INHIBITION; MYELOMONOCYTIC LEUKEMIA; PROMYELOCYTIC LEUKEMIA; TUMOR SUPPRESSOR GENE; CELL CYCLE CHECKPOINT; DRUG EFFECTS; METABOLISM; MICROTUBULE; MITOSIS; TUMOR CELL LINE;

APOPTOSIS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; HUMANS; MICROTUBULES; MITOSIS; NOSCAPINE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; TUMOR SUPPRESSOR PROTEINS;

EID: 84938780257     PISSN: None     EISSN: 18387640     Source Type: Journal    
DOI: 10.7150/thno.10844     Document Type: Article

References (39)

1. Inaba H, Greaves M, Mullighan CG. Acute lymphoblastic leukaemia. Lancet. 2013; 381: 1943-55.
2. Ye K, Ke Y, Keshava N, et al. Opium alkaloid noscapine is an antitumor agent that arrests metaphase and induces apoptosis in dividing cells. Proc Natl Acad Sci U S A. 1998; 95: 1601-6.
3. Joshi HC, Zhou J. Noscapine and analogues as potential chemotherapeutic agents. Drug News Perspect. 2000; 13: 543-6.
4. Haikala V, Sothmann A, Marvola M. Comparative bioavailability and pharmacokinetics of noscapine hydrogen embonate and noscapine hydrochloride. Eur J Clin Pharmacol. 1986; 31: 367-9.
5. Ke Y, Ye K, Grossniklaus HE, et al. Noscapine inhibits tumor growth with little toxicity to normal tissues or inhibition of immune responses. Cancer Immunol Immunother. 2000; 49: 217-25.
6. Aneja R, Zhou J, Vangapandu SN, et al. Drug-resistant T-lymphoid tumors undergo apoptosis selectively in response to an antimicrotubule agent, EM011. Blood. 2006; 107: 2486-92.
7. Zhou J, Gupta K, Aggarwal S, et al. Brominated derivatives of noscapine are potent microtubule-interfering agents that perturb mitosis and inhibit cell proliferation. Mol Pharmacol. 2003; 63: 799-807.
8. Aneja R, Vangapandu SN, Joshi HC. Synthesis and biological evaluation of a cyclic ether fluorinated noscapine analog. Bioorg Med Chem. 2006; 14: 8352-8.
9. Naik PK, Chatterji BP, Vangapandu SN, et al. Rational design, synthesis and biological evaluations of amino-noscapine: a high affinity tubulin-binding noscapinoid. J Comput Aided Mol Des. 2011; 25: 443-54.
10. Zhou J, Panda D, Landen JW, et al. Minor alteration of microtubule dynamics causes loss of tension across kinetochore pairs and activates the spindle checkpoint. J Biol Chem. 2002; 277: 17200-8.
11. Zhou J, Gupta K, Yao J, et al. Paclitaxel-resistant human ovarian cancer cells undergo c-Jun NH2-terminal kinase-mediated apoptosis in response to noscapine. J Biol Chem. 2002; 277: 39777-85.
12. Landen JW, Hau V, Wang M, et al. Noscapine crosses the blood-brain barrier and inhibits glioblastoma growth. Clin Cancer Res. 2004; 10: 5187-201.
13. Masoumi KC, Shaw-Hallgren G, Massoumi R. Tumor Suppressor Function of CYLD in Nonmelanoma Skin Cancer. J Skin Cancer. 2011; 2011: 614097.
14. Massoumi R. CYLD: a deubiquitination enzyme with multiple roles in cancer. Future Oncol. 2011; 7: 285-97.
15. Wu W, Zhu H, Fu Y, et al. Clinical significance of down-regulated cylindromatosis gene in chronic lymphocytic leukemia. Leuk Lymphoma. 2014; 55: 588-94.
16. Ye H, Liu X, Lv M, et al. MicroRNA and transcription factor co-regulatory network analysis reveals miR-19 inhibits CYLD in T-cell acute lymphoblastic leukemia. Nucleic Acids Res. 2012; 40: 5201-14.
17. Gao J, Huo L, Sun X, et al. The tumor suppressor CYLD regulates microtubule dynamics and plays a role in cell migration. J Biol Chem. 2008; 283: 8802-9.
18. Wickstrom SA, Masoumi KC, Khochbin S, et al. CYLD negatively regulates cell-cycle progression by inactivating HDAC6 and increasing the levels of acetylated tubulin. EMBO J. 2010; 29: 131-44.
19. Yang Y, Liu M, Li D, et al. CYLD regulates spindle orientation by stabilizing astral microtubules and promoting dishevelled-NuMA-dynein/dynactin complex formation. Proc Natl Acad Sci U S A. 2014; 111: 2158-63.
20. Stegmeier F, Sowa ME, Nalepa G, et al. The tumor suppressor CYLD regulates entry into mitosis. Proc Natl Acad Sci U S A. 2007; 104: 8869-74.
21. Sun L, Gao J, Huo L, et al. Tumour suppressor CYLD is a negative regulator of the mitotic kinase Aurora-B. J Pathol. 2010; 221: 425-32.
22. Yang Y, Ran J, Liu M, et al. CYLD mediates ciliogenesis in multiple organs by deubiquitinating Cep70 and inactivating HDAC6. Cell Res. 2014; 24: 1342-53.
23. Gao J, Sun L, Huo L, et al. CYLD regulates angiogenesis by mediating vascular endothelial cell migration. Blood. 2010; 115: 4130-7.
24. Tala, Xie S, Sun X, et al. Microtubule-associated protein mdp3 promotes breast cancer growth and metastasis. Theranostics. 2014; 4: 1052-61.
25. Wang H, Liu B, Zhang C, et al. Parkin regulates paclitaxel sensitivity in breast cancer via a microtubule-dependent mechanism. J Pathol. 2009; 218: 76-85.
26. Zhou J, Giannakakou P. Targeting microtubules for cancer chemotherapy. Curr Med Chem Anticancer Agents. 2005; 5: 65-71.
27. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer. 2004; 4: 253-65.
28. Weaver BA, Cleveland DW. Decoding the links between mitosis, cancer, and chemotherapy: The mitotic checkpoint, adaptation, and cell death. Cancer Cell. 2005; 8: 7-12.
29. Arora M, Kaul D, Varma N, et al. Cellular proteolytic modification of tumor-suppressor CYLD is critical for the initiation of human T-cell acute lymphoblastic leukemia. Blood Cells Mol Dis. 2015; 54: 132-8.
30. Liu P, Xu B, Shen W, et al. Dysregulation of TNFalpha-induced necroptotic signaling in chronic lymphocytic leukemia: suppression of CYLD gene by LEF1. Leukemia. 2012; 26: 1293-300.
31. Espinosa L, Cathelin S, D'Altri T, et al. The Notch/Hes1 pathway sustains NF-kappaB activation through CYLD repression in T cell leukemia. Cancer Cell. 2010; 18: 268-81.
32. Bonapace L, Bornhauser BC, Schmitz M, et al. Induction of autophagy-dependent necroptosis is required for childhood acute lymphoblastic leukemia cells to overcome glucocorticoid resistance. J Clin Invest. 2010; 120: 1310-23.
33. Li D, Gao J, Yang Y, et al. CYLD coordinates with EB1 to regulate microtubule dynamics and cell migration. Cell Cycle. 2014; 13: 974-83.
34. Sun SC. CYLD: a tumor suppressor deubiquitinase regulating NF-kappaB activation and diverse biological processes. Cell Death Differ. 2010; 17: 25-34.
35. Reiley W, Zhang M, Sun SC. Negative regulation of JNK signaling by the tumor suppressor CYLD. J Biol Chem. 2004; 279: 55161-7.
36. Yang Y, Sun L, Tala, et al. CYLD regulates RhoA activity by modulating LARG ubiquitination. PLoS One. 2013; 8: e55833.
37. Rouzier R, Rajan R, Wagner P, et al. Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer. Proc Natl Acad Sci U S A. 2005; 102: 8315-20.
38. Luo Y, Li D, Ran J, et al. End-binding protein 1 stimulates paclitaxel sensitivity in breast cancer by promoting its actions toward microtubule assembly and stability. Protein Cell. 2014; 5: 469-79.
39. Sun X, Li D, Yang Y, et al. Microtubule-binding protein CLIP-170 is a mediator of paclitaxel sensitivity. J Pathol. 2012; 226: 666-73.